Related Experiment Video
Updated: Aug 14, 2026
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy
Published on: October 4, 2019
A cDNA-microarray analysis of camptothecin resistance in glioblastoma cell lines
Elena Morandi1, Chiara Zingaretti, Daniela Chiozzotto
1Fenice Environmental Research Center, Via Ciro Menotti 48, 48023 Marina di Ravenna, Ravenna, Italy.
Abstract:
Chemotherapy, as generally available, is of a limited value in curing malignant brain tumors (gliomas), which often develop resistance to drugs, becoming completely unresponsive to any standard therapeutic approach. Camptothecins, a family of topoisomerase I inhibitor drugs, represent a new promising treatment strategy and are currently under evaluation for testing the clinical efficacy. We selected a CPT-resistant sub-line (U87CPT-R) from U87-MG grade III-IV astrocytoma cells, and compared the expression profile of the two cell lines by cDNA-microarray, as a preliminary screening of the molecular mechanisms involved in the acquisition of CPT resistance in glioma cells. The relevant role of IL-1 beta overproduction as well as a generalised up-regulation of genes implicated in angiogenesis and inflammatory response are discussed in details.
Insights
This study investigated drug resistance in brain tumors. Researchers found that interleukin-1 beta and genes related to inflammation and angiogenesis play a role in chemotherapy resistance in glioma cells.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Malignant brain tumors, particularly gliomas, exhibit limited response to conventional chemotherapy.
- Acquired drug resistance significantly reduces the efficacy of standard therapeutic approaches for gliomas.
- Camptothecins, inhibitors of topoisomerase I, are emerging as a promising therapeutic strategy for brain tumors.
Purpose of the Study:
- To investigate the molecular mechanisms underlying camptothecin (CPT) resistance in glioma cells.
- To compare the gene expression profiles of CPT-sensitive and CPT-resistant glioma cell lines.
- To identify potential molecular targets for overcoming CPT resistance in malignant brain tumors.
Main Methods:
- Development of a CPT-resistant glioma cell line (U87CPT-R) from a parental U87-MG astrocytoma cell line.
- Utilisation of cDNA-microarray analysis to compare gene expression profiles between the two cell lines.
- Bioinformatic analysis to identify differentially expressed genes and associated pathways.
Main Results:
- Identification of significant differences in gene expression between U87CPT-R and U87-MG cells.
- Overexpression of interleukin-1 beta (IL-1 beta) in the CPT-resistant cell line.
- Upregulation of genes associated with angiogenesis and inflammatory response in CPT-resistant glioma cells.
Conclusions:
- Interleukin-1 beta overproduction is implicated in the development of CPT resistance in glioma.
- Enhanced angiogenesis and inflammatory responses contribute to acquired drug resistance in malignant brain tumors.
- Understanding these molecular mechanisms may lead to novel therapeutic strategies for overcoming chemotherapy resistance in gliomas.
